Back to top

Image: Bigstock

Masimo Corporation

Read MoreHide Full Article

Masimo's first quarter 2016 results were impressive. The company also raised its full-year 2016 earnings guidance. Lower expense guidance will also boost bottom-line growth. We believe the company's innovative product portfolio is a key growth catalyst. Wider adoption of non-invasive patient monitoring technology will help the company gain market traction. Masimo’s SET pulse oximetry business represents considerable growth opportunities in international markets.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Masimo Corporation (MASI) - free report >>

Published in